编程细胞死亡蛋白1/编程细胞死亡配体1（PD-1 / PD-L1）检查点抑制剂已成为临床革命的前沿，在其中，靶向PD-L1治疗在患有实体瘤的患者中取得了一些成功。大量临床试验表明，PD-L1单药和联合疗法均可显着抑制某些肿瘤的生长并促进患者的存活。目前，抗PD-L1治疗已被用作肺癌、乳腺癌、头颈部鳞状细胞癌和膀胱上皮癌标准治疗的一部分。尽管许多证据已经表明PD-L1抗体在大多数患者中是安全的，但仍然存在一些不良反应，例如肺炎、肝炎、结肠炎、神经事件和心肌炎。在本综述中，介绍了实体肿瘤中durvalumab的临床信息，包括其疗效和安全性，以掌握靶向PD-L1治疗的当前应用情况，并为临床应用提供指导。 版权所有© Bentham Science Publishers，请发送电子邮件至epub@benthamscience.net以获得任何查询。

Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) checkpoint inhibitors have been on the front line of clinical revolution in which, the targeted PD-L1 therapy has obtained some success in patients with solid tumors. A large number of clinical trials revealed that both monotherapy and combination therapy of PD-L1 antibody significantly suppress some tumor growth and promote the survival of patients. At present, anti-PD-L1 treatment has been used as a portion of standard treatment for lung cancer, breast cancer, head and neck squamous cell carcinoma, and urothelial carcinoma. Although much evidence has demonstrated that PD-L1 antibody is safe in most patients, there are still some adverse reactions, such as pneumonitis, hepatitis, colitis, neurologic events and myocarditis. In this review, the clinical information, including the efficacy and safety of durvalumab in solid tumors, was enumerated and summarized at this stage to grasp the current application of targeted PD-L1 therapy and provide guidance for clinical application.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.